News & AnalysisGlobal Health

Disappointing Results Blunt Hopes for Malaria Vaccine

See allHide authors and affiliations

Science  16 Nov 2012:
Vol. 338, Issue 6109, pp. 871-872
DOI: 10.1126/science.338.6109.871

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

This article has a correction. Please see:

Summary

New trial results from the most advanced candidate vaccine for malaria, now in development for more than 2 decades, show that the vaccine lowers the risk of clinical episodes of malaria by only 31% among babies who receive their first dose between 6 and 12 weeks of age. The results dampen the hope that the vaccine, called RTS,S, might be used as part of babies' routine vaccinations in the first months of life. That would have been by far the easiest way to administer it, because the public health infrastructure is already in place.

  • * With reporting by Leslie Roberts.